focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
...since we had news of the outline contract to work with Hangzhou Water towards a desalination plant on Xugong Island. In the September half year report there was a line about contract negotiations being slow but don't think we've heard anything else. Anyone know anything?
Here's a link that's a bit more interesting than today's RNS - more information, or at least confirmation, about progress towards a domestic machine and about the strategy to license bead technology. Only disappointing element is the lazy sexist stereotyping - hope that's not the new marketing approach: http://www.yorkshirepost.co.uk/business/business-news/xeros-sets-sights-on-homes-for-laundry-revolution-1-6994703
Try this link (you do have to register with your email address first): http://wsw.com/webcast/jeff86/register.aspx?conf=jeff86&page=trx.l&url=http://wsw.com/webcast/jeff86/trx.l/
Just listened online to a terrific presentation from Antony Odell to the Jefferies Health Care Conference today - filled in all sorts of gaps in my knowledge about the company and its strategy. It's about 35 mins long but fascinating stuff if you are in or thinking about getting in to this company. Gave lots of information on the short term prospects (including confirmation that first patients should be recruited to the meniscus trial before Xmas) as well as key developments over the next two years. Finished with some inspiring possibilities for the next decade concerning potential for decelluarisation in areas including hip joints, heart valves (lots of data there already) arteries ("tubes and plumbing"), bone cartilage and even the liver. I followed the link in a tweet from the company this morning but afraid I can't seem to paste the link - it's not on the company website at the moment but I assume it will be soon. Will post a link when I can find it.
Ok, so not a great reaction to our figures but I'm not that surprised - I suspect some people thought we'd already be making big money and were scared off when they saw we'd achieved sales of eight grand. Worth noting of course that these results are until the end of July - so only six weeks into the commercialisation. As I've said before, would be good to start hearing some success stories to back up the results of the University of Manchester trial. With this new Q code the market would seem to expand considerably from January. For those interested, there's now more details available on the UK (and, it appears, Poland) trial for meniscus replacement. I'm no medical expert but a bit of googling (DYOR!) suggests they've got the top guys in the knee world involved here. Not open to volunteers yet but it all seems ready to go - it's a three-year study but I'd imagine there will be information from patient questionnaires relating to knee movement and pain relief well before the end. Anyway I found details here: http://clinicaltrials.gov/ct2/show/NCT02270905?term=Meniscus&rank=5
I certainly am, though as someone fairly new to investing I'm having to lengthen the timeframes I'd initially envisaged for these companies to make me any money. I think they will, and its exciting watching them grow, but unless maybe we get bought out, it's going to take a while.
Looks like Neil Woodford agrees with us. He's not having my shares just yet though.
So...judging by the lack of any dramatic change, the results seem to be pretty much accepted by the market as par for the course at this stage. Revenue increasing but a fair way to go before profits are made, but that's mainly because we're spending money to gear up for expansion. I can understand why with that narrative some will be reluctant to jump in too far at this stage, but am encouraged by the fact those people typically say they will "keep an eye on us". Every reason to remain optimistic here I'd have thought.
I'm optimistic in the medium to long term but I do think it's still early days for this company. I'm not expecting great results as in making the kind of money that will pull in big investors - the good news comes in ratcheting up the number of hotels and laundries making the leap and then getting serious word of mouth out about the savings and the improved performance. That does seem to happening and the sp is holding up nicely - good rise today of course - but I'm not expecting anything too dramatic in the results this year.
This is all great - though what I really want to hear now is the results of the commercial use of dermapure in the US - not necessarily at this stage in terms of sales revenue, but clinical success. Last year's trials research was so promising in terms of success in addressing chronic problems, to get that backed up by results in the field would be quite something.
I like seeing a steady stream of articles like this: http://www.clickgreen.org.uk/news/national-news/125104-waterless-washing-machine-saves-25m-litres-of-water-in-just-6-months.html Don't suppose Click Green has a huuuuuuge readership but anything that gets the company talked about positively is great at this stage.
Very nice rise ahead of tomorrow's interim results. Hope they don't disappoint - this is becoming a real star of my portfolio.
Yes I do remember seeing a bit of film a while back from a happy patient on a trial and it was hugely convincing. Now that the product is more widely available I hope they are digging up more stories. I'm sure this company has an exciting future - so glad to have got in at 15.
The sp is doing quite nicely this week but I am a little surprised there's not more of a pr offensive. I worked as a press officer for a while and if this was my business I think I'd would be issuing media releases - not rns, just basic pr - showing happy workers packing off the first orders and finding patients in small towns across the USA for case studies who have had troublesome wounds or ulcers clear up - there must be some aren't there? Aren't there? Maybe it's all in the pipeline. You don't do these things expecting huge coverage, it's just about keeping everyone's (your staff as much as shareholders) enthusiasm up about a product launch and showing a bit more evidence of activity than some of the slightly vague statements so far.
Further to today's rns - I'm pleased they've now got a Spanish language website, but makes me wonder just how hard they've been trying over the last ten years in South America without one.
The statement on dividends seems deliberately obfuscatory - the word "therefore" appears especially redundant. They've just decided to hang on to the money for now. I couldn't find reference to a November 14 dividend either.